{"name":"Graybug Vision","slug":"graybug-vision","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":15234000,"netIncome":-29562000,"cash":11520000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOLXp6bV9lejNlMmhhalBkTVh5M3g4d28ycElrb0FMTVAtS2hRM1NxN3hlRVgyQWtzZHZmTTI5NWZBRUNUR0RPYVhReWRXcDRTSVpxU2VKeGhMNmlVeFVpaExrUUdVbmVYUTI3MVBHbDJfZHN6WVU1bnp3ampaUzRfRzlUbUtoR3lPUDlybVhMWDVOdDQ1Z0E?oc=5","date":"2026-03-24","type":"pipeline","source":"PharmaTimes","summary":"Qlaris Bio appoints Fred Guerard as President and CEO - PharmaTimes","headline":"Qlaris Bio appoints Fred Guerard as President and CEO","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPZFVOVFhlZm9TaUZvTmxYc2VTZFJzekJub0QwNnZuYkhqZ2VQNUh5Y2NrVkJLYXJGeDE4ZGthU2ZIOTdHN2dIc0VCRHo3dWdEcE1Sa2NhbkhPcGlXXzBEdUpfOWltbmk0OFRYQkN4WllFdEhtMjBKVmRyYlBZSEhIYUk5SnZtVDRkMHNIc1hTcw?oc=5","date":"2026-03-10","type":"pipeline","source":"citybiz","summary":"Qlaris Bio Appoints Fred Guerard, Pharm.D., as CEO - citybiz","headline":"Qlaris Bio Appoints Fred Guerard, Pharm.D., as CEO","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPOUVfdGdCVTV4Y1p6M0lhMGFXalp2Y0ZuT0JqSlhtdjkwQWxsdW4yRTNBQnU3bnRnZ1lwNXJLX1R4VFVNWXl1cHdDTndkUGpkOFMyczkta0dqR2FJU2JWNjFIemYzSklmMzJGLVV5OFlIcWV4NXpOVDhBV004Y3V0QnBVRGdmS2Mxc1V1VWhlN3A0eUxWSWRRVG11QmxOcDl5UEJBTl8yY2JXc24tSFdjRGdFTUpCQUdjbGM4NkVwXy1md3NsUTZtalF5bF9id0o3QXoxNldlU00xNXdKRUMxX2tvRXdmUEFtdTNQME9hU25qTXRxeW1SN1V2MnRlejJETGU3UlUwaVdPeWVYVXVScw?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire UK","summary":"Persistent Corneal Edema Market to Show Impressive Growth at a CAGR of 21.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Persistent Corneal Edema Market to Show Impressive Growth at a CAGR of 21.8% During the Forecast Period (2025-2034) | De","sentiment":"neutral"},{"date":"2025-11-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOYlE1bDB1YnJCNjQ0QVBTMWdxb1ZwXzhLTFQ5ZHhEbWxWbnF1U2g1OGFydDlWYW1Pb1I2WklXdzNXZkhSSmFCUGVEX3ZWemg3VmhoSXd6WlY3X3JqZHpLYnZGY3JQWVdKOEcybWQzRHhyamFDSDJBckcxYngyd3hTS1kza0RqbXR2SVR2dnkyOGZWQ0ZXVzV0bXpzcF9UenFvRmFVQnlZU3NuaHlEcG10SHY0Z0pxOG1rdjQ2WGpSZnAxYWFFQjBENkZwNHMxc190S1dNdGE2Y3ZlZ21fVWV2OTJtX2NSaEd5Vm1nLTBpMGpsRnRnVFVHNmRNVUZ5NkhvX2pXaXlDQ0wwckEwR2c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire","headline":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Dire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1JNzA4clpHMXhOLVJwYjdtSDNUdGNfMndyY1dvR3U4ODVzZDhJcndNSV9kRVFXbzJ1LVIxbXZwdG1EcEpzS1dsTGxyU2t5cWlQVWlkTEVWQTJlWHR4alRQOHB5YTNRQQ?oc=5","date":"2025-02-14","type":"pipeline","source":"Market.us","summary":"Branch Retinal Vein Occlusion (BRVO) - Market.us","headline":"Branch Retinal Vein Occlusion (BRVO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNa3cwNnpVTjlCeVJMWXNKRERGUkJfdkt6T2R4c2JzYjVNQU9YN1k3NUJsQkRNaUlBdDJMZ0dvSDdFeUJmTFNjUnI1aXRiT2pmTHkyU2xQVkk0M0MtdVR2UDFGSjVMOUM4dXloNnFnWDk5VEFJWE16dThFam5Yc1ljNnZiY2E4d3htaERPaHRFcGJITmM?oc=5","date":"2024-10-11","type":"pipeline","source":"grandviewresearch.com","summary":"India Retinal Disorder Treatment Market Size & Outlook, 2030 - grandviewresearch.com","headline":"India Retinal Disorder Treatment Market Size & Outlook, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPZWJ0UFVWeVpsclFvVjN3SzZ4OUg3d3VqSjQzRXdWdzVUcnp3Z1pvNDlCTlBISWo1LTJEaU0zSi1CVDRTN3VjSlRJSktpRW85S3loMHJWaG5MaW1GMUdiSFJudDVzQklmQlg2V0xBOThucTRNRGFkdU1sY1dBeTZjMnptQjVhcDE3aDdfa1YtRnVieExCX2RaQnQ4bVNlZkZralpBOUtlV1lzWVZNZzZrelpNUXQ3R2h0cUE?oc=5","date":"2024-09-10","type":"trial","source":"Eyes On Eyecare","summary":"Opthea names senior leaders ahead of phase 3 wet AMD data readout - Eyes On Eyecare","headline":"Opthea names senior leaders ahead of phase 3 wet AMD data readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOaWE3UG5JVFRINkRXNVdWMk1nS05feERObWpSMnhSQzV1c3JqQjY1M3ZfdktUNlNUUDUtbnVjWFNnaDQ2N3lwbktLZEpYYVJYMEZVbHNZQnJtTHo0elVoLWpQYVFodUJ4UlBKMm5idUdmdENtdHdQbERueXdzdmlJWTlrZUxCNkxLTUJzRmV6akVDWlU?oc=5","date":"2023-10-30","type":"pipeline","source":"Eyes On Eyecare","summary":"Opthea names new US-based leadership - Eyes On Eyecare","headline":"Opthea names new US-based leadership","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15234000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-29562000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":11520000,"cashHistory":[],"totalAssets":13591000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}